Introduction {#S1}
============

We usually study *in vitro* T cell responses at the atmospheric O~2~ concentration of 21%. However, oxygen tensions in lymphoid tissues are markedly lower (\<5%) than those found in peripheral arterial blood (13%)^[@R1],\ [@R2]^. Immune cells are exposed to varying oxygen tensions in lymphoid organs^[@R2]^. T cells are activated during antigen recognition at inflammatory or tumor sites, both of which are hypoxic^[@R2]^. Moreover, hypoxic extracellular environments exist in healthy and diseased non-lymphoid tissues, including adipose tissue^[@R3]^, skin^[@R4]^ and the gastrointestinal tract^[@R5]^. Therefore, activated T cells are dependent on an intracellular machinery that enables them to adapt to changes in oxygen tension and execute their functions *in situ*. The transcription factor hypoxia-inducible factor 1 (HIF-1), mediates at least some of the required metabolic switches from oxidative phosphorylation to aerobic glycolysis in response to hypoxia^[@R6]^.

The HIF-1 complex consists of two subunits, HIF-1α and HIF-1β^[@R7]^. Under normoxic conditions, HIF-1α is proline hydroxylated by prolyl hydroxylases (PHDs) that promotes its binding to the von Hippel Lindau protein (VHL) E3 ligase complex, followed by HIF-1α ubiquitination and proteasomal degradation^[@R8],\ [@R9]^. Hypoxic conditions inhibit HIF-1α degradation and lead to its stabilization. Recently, a further regulatory layer in non-lymphocytes was described, revealing that in intestinal epithelial cells *Hif1a* is negatively regulated by microRNA-155 (miR-155) during prolonged hypoxia^[@R10]^.

In addition to the cellular response to hypoxia, HIF-1 plays an important role in regulating T~H~17 differentiation. T~H~17 cells mount responses against extracellular bacterial and fungal infections in the intestine and the airways^[@R11]^. Despite the benefit of such immune responses, T~H~17 cells can also play immunopathologic roles in experimental as well as naturally occurring autoimmune settings, including collagen-induced arthritis, experimental autoimmune encephalomyelitis (EAE) or inflammatory bowel diseases (IBD)^[@R12]-[@R14]^. HIF-1 promotes T~H~17 differentiation by directly inducing *Rorc* transcription and subsequently collaborates with RORγt to regulate downstream T~H~17 genes and inhibiting regulatory T cell (T~reg~) differentiation through an active process that targets Foxp3 protein for degradation^[@R15]^. In addition, deficiency of *Hif1a* in T cells diminishes the expression of glycolytic molecules and alters the dichotomy between these two T cell subsets, demonstrating that HIF-1α induces metabolic reprogramming and orchestrates lineage differentiation of T cells^[@R16]^.

miRNAs are noncoding single-stranded RNAs of about 22 nucleotides that mediate sequence-dependent posttranscriptional negative regulation of gene expression^[@R17]^. Various stresses, including hypoxia, regulate miRNA expression and function^[@R18]^. For example, a subset of miRNAs induced by hypoxia, referred to as "hypoxamiRs", contribute to the regulation of the broad spectrum of genes regulated by hypoxia. Among these miRNAs, miR-210 is the master hypoxamiR and regulates a variety of cellular events in non-lymphoid tissues^[@R19]-[@R22]^.

Recent work has identified miRNAs as pivotal regulators of helper T cell differentiation and function^[@R23],\ [@R24]^. Two genome-wide miRNA-profiling studies in activated T cells revealed that miR-210 is highly expressed after T cell stimulation^[@R25],\ [@R26]^. However, *Mir210*-regulation and its role in T cell activation and differentiation have not been studied.

Results {#S2}
=======

T cell activation robustly induces *Mir210* {#S3}
-------------------------------------------

Two independent studies of global miRNA expression profiling in lymphocytes reported that miR-210 is highly expressed in activated mouse T cells (**[Supplementary Fig. 1](#SD7){ref-type="supplementary-material"}**)^[@R25],\ [@R26]^. To address the miR-210 expression pattern in more detail, we assessed the expression of miR-210 during T cell activation by real-time PCR (RT-PCR) following the stimulation of naive mouse CD4^+^ T cells with anti-CD3 and anti-CD28. TCR-CD28 stimulation led to an over 500-fold increase in miR-210 abundance in CD4^+^ T cells that were activated for 4 d compared to unstimulated cells (**[Fig. 1a](#F1){ref-type="fig"}**). In contrast to interleukin 2 (*Il2*), which was rapidly upregulated by 12 h post stimulation, miR-210 abundance increased more slowly and reached highest amounts at 4 d after T cell activation, suggesting a possible regulatory role of miR-210 in later stages of T cell activation and function (**[Fig. 1a,d](#F1){ref-type="fig"}**). We tested whether induction of *Mir210* also occurs *in vivo* in activated CD4^+^ T cells using two different approaches. First, we examined miR-210 expression in homeostatically expanded CD4^+^ T cells isolated from various lymphoid tissues. To this end, naive CD4^+^ T cells were sorted and adoptively transferred into congenic *Rag2*^−/−^ mice. After 3 weeks, we harvested cells from the spleen, inguinal lymph nodes (ILNs), mesenteric lymph nodes (MLNs), lung and small intestine. After their homeostatic expansion, the transferred CD4^+^ T cells isolated from the different tissues displayed a uniform, memory-like (CD44^hi^ CD62L^--^) phenotype and all of the samples moderately upregulated miR-155, an antigen stimulation-induced microRNA^[@R27]^ (**[Fig. 1b](#F1){ref-type="fig"}** and **[Supplementary Fig. 2a](#SD7){ref-type="supplementary-material"}**). miR-210 was also upregulated in these T cells, but unlike miR-155, miR-210 showed a distinct expression pattern, with much higher expression in CD4^+^ T cells isolated from hypoxic tissues like the small intestine, compared to CD4^+^ T cells isolated from relatively normoxic tissues like the lung. This suggests that miR-210 might play a more critical role in T cells residing within hypoxic sites. We also tested the *in vivo* induction of *Mir210* following ovalbumin (OVA) immunization. We transferred naive CD4^+^ T cells isolated from OT-II TCR-transgenic mice (specific for the OVA-peptide 323--339) into congenic recipient mice, followed by OVA challenge. Compared to naive T cells, miR-210 was markedly upregulated in these T cells (**[Fig. 1c](#F1){ref-type="fig"}**). Similarly, *Mir210* was robustly induced during CD8^+^ T cell activation both by *in vitro* stimulation and by using a mouse model of lymphocytic choriomeningitis virus (LCMV) infection (**[Supplementary Fig. 2b,c](#SD7){ref-type="supplementary-material"}**). Collectively, these data suggest that T cell activation leads to markedly increased miR-210 expression both *in vitro* and *in vivo*.

To study how *Mir210* is regulated during T cell differentiation, naive CD4^+^ T cells were *in vitro* polarized into T~H~1, T~H~2, T~H~17 and T~reg~ cells and the time-dependent appearance of miR-210 was measured during the process of polarization. The highest increase in miR-210 was observed in T~H~17 cells, suggesting a preferential role of miR-210 in T~H~17 polarization or function (**[Fig. 1d](#F1){ref-type="fig"}**).

CD28-- but not IL-2--signaling controls *Mir210* expression {#S4}
-----------------------------------------------------------

To examine whether CD28-mediated costimulation is involved in the upregulation of *Mir210*, we stimulated naive CD4^+^ T cells using anti-CD3 in the absence or presence of anti-CD28. miR-210 abundance in samples costimulated with anti-CD28 was 6-fold higher than in samples that were stimulated with anti-CD3 alone (**[Fig. 2a](#F2){ref-type="fig"}**). Since CD28 costimulation is known to promote IL-2 production^[@R28]^ and the induction of *Il2* transcripts preceded the induction of *Mir210* (**[Fig. 1a](#F1){ref-type="fig"}**), we investigated whether CD28-mediated costimulation might indirectly induce *Mir210* by assessing miR-210 abundance in IL-2--deficient, CD4^+^ T cells (**[Fig. 2b](#F2){ref-type="fig"}**). Whereas the expression of the IL-2-regulated miR-182 in IL-2--deficient CD4^+^ T cells was markedly reduced following TCR stimulation (**[Fig. 2b](#F2){ref-type="fig"}** top)^[@R29]^, IL-2--deficiency had no effect on miR-210 expression, suggesting that IL-2 signaling is not required for the induction of *Mir210* (**[Fig. 2b](#F2){ref-type="fig"}** bottom).

Since phosphatidylinositol-3-OH kinase (PI(3)K) signaling is a major CD28 downstream signaling pathway^[@R30]^, we addressed the requirement of PI(3)K for the induction of *Mir210* with small molecule inhibitors of enzymes involved in the PI(3)K signaling pathways. Whereas CP550690, an inhibitor of Jak1 and Jak3, showed no inhibitory effect on the expression of miR-210 in TCR--CD28-stimulated T cells, both PI(3)K (LY294002 and GDC-0941) and mTOR (rapamycin and MLN0128) inhibitors potently suppressed miR-210 expression (**[Fig. 2c](#F2){ref-type="fig"}**). Thus, the induction of *Mir210* in activated T cells is dependent upon the PI(3)K--mTOR pathway.

HIF-1α is required for *Mir210* induction {#S5}
-----------------------------------------

To study the influence of hypoxia on the regulation of *Mir210* in T lymphocytes, we compared the induction of *Mir210* in resting versus anti-CD3 and anti-CD28 stimulated primary CD4^+^ T cells under normoxic (21% O~2~) or hypoxic (1% O~2~) conditions. TCR stimulation under normoxia resulted in a robust but delayed upregulation of miR-210 (**[Fig. 3a](#F3){ref-type="fig"}**). Unstimulated, T cells increased miR-210 abundance only modestly under hypoxic conditions, suggesting that in T cells, unlike other cell types, hypoxia alone is insufficient to induce robust miR-210 expression. However, stimulated CD4^+^ and CD8^+^ T cells exhibited rapid and markedly increased expression of miR-210 in hypoxia, suggesting a synergistic effect of TCR-stimulation and hypoxia (**[Fig. 3a](#F3){ref-type="fig"}** and **[Supplementary Fig. 2b](#SD7){ref-type="supplementary-material"}**). Notably, this observation was specific for miR-210 since the abundance of miR-155 was not affected by oxygen tension during T cell activation (**[Supplementary Fig. 2d](#SD7){ref-type="supplementary-material"}**).

Since HIF-1α is the master regulator of hypoxic gene expression, we reasoned that HIF-1α might regulate *Mir210* in T lymphocytes, as shown for other cell types^[@R31]^. Therefore, we compared HIF-1α protein abundance in resting versus TCR-stimulated CD4^+^ T cells under normoxic or hypoxic conditions. TCR-stimulation under both settings resulted in the accumulation of HIF-1α protein by 24 h (**[Fig. 3b,c](#F3){ref-type="fig"}**). Consistent with miR-210 expression, hypoxia also led to more HIF-1α protein than in normoxia on day 1. Similar results were also found after CD8^+^ T cell activation (**[Supplementary Fig. 3a](#SD7){ref-type="supplementary-material"}**). The observations that both miR-210 and HIF-1α expression were regulated by oxygen tension and that the expression of HIF-1α preceded the induction of *Mir210* support the notion that HIF-1 acts upstream of miR-210. Furthermore, we found that CD28-- deficiency resulted in substantial reductions of HIF-1α protein in activated T cells (**[Supplementary Fig. 3b](#SD7){ref-type="supplementary-material"}**), indicating that TCR-CD28 signaling may induce *Mir210* via HIF-1α.

To test this hypothesis, we studied TCR signaling-induced *Mir210* expression under normoxic conditions in the presence or absence of HIF-1α. Whereas in HIF-1α--sufficient T cells anti-CD3--anti-CD28 stimulation resulted in robust upregulation of both *Hif1a* transcripts and miR-210, the induction of *Mir210* was markedly attenuated in a HIF-1α--deficient background (**[Fig. 3d](#F3){ref-type="fig"}** left and middle), indicating that HIF-1α is required for *Mir210* induction in activated T cells. The deficiency of HIF-1α did not affect global activation of CD4^+^ T cells since miR-182 expression was largely unaffected by deletion of *Hif1a* (**[Fig. 3d](#F3){ref-type="fig"}** right). Consequently, we reanalyzed a ChIP-seq dataset, performed in a recent study^[@R32]^ with T~H~17 polarized cells, which revealed that after T cell activation HIF-1α directly bound the promoter region of *Mir210*, with a binding peak at about 400 bp upstream of the *Mir210* sequence (**[Supplementary Fig. 3c](#SD7){ref-type="supplementary-material"}**), thereby demonstrating that *Mir210* is a direct downstream target of HIF-1α in activated T~H~17 cells.

Whereas HIF-1α protein abundance was sustained until 2 d post stimulation in normoxia, HIF-1α protein amounts markedly decreased between d 1 and d 2 under hypoxic conditions (**[Fig. 3b,c](#F3){ref-type="fig"}**). Under normoxic conditions, the decrease in HIF-1α protein was detected later, between d 2 and d 3 after TCR stimulation. In both cases, the decrease in HIF-1α protein correlated with increases in miR-210 abundance, raising the possibility that HIF-1α could be both an upstream *Mir210* regulator and a miR-210 target (**[Fig. 3b,c](#F3){ref-type="fig"}**). Similar results were observed in CD8^+^ T cells activated under normoxic or hypoxic conditions (**[Supplementary Fig. 2b, 3a](#SD7){ref-type="supplementary-material"}**).

T cell-specific deletion of *Mir210* {#S6}
------------------------------------

To investigate the role of miR-210 in T cells, mice with *lox*P-flanked *Mir210* alleles (*Mir210*^f/f^)^[@R33]^ were crossed with CD4-Cre transgenic mice to delete the floxed *Mir210* alleles in T cells (hereafter referred to as *Mir210*^--/--^ mice). RT-PCR analysis indicated efficient deletion (\>98%) of *Mir210* in activated T cells (**[Supplementary Fig. 4a](#SD7){ref-type="supplementary-material"}**). Consistent with low miR-210 abundance in immature thymocytes (**[Supplementary Fig. 4a](#SD7){ref-type="supplementary-material"}**), miR-210--deficiency had little effect on T cell development (**[Fig. 4a](#F4){ref-type="fig"}**). Moreover, wild-type and *Mir210*^--/--^ mice had comparable numbers and distributions of CD4^+^ and CD8^+^ T cells in the periphery and the expression of CD62L and CD44 on peripheral CD4^+^ T cells was unaffected by deletion of *Mir210* in 6-8 week old mice (**[Fig. 4b](#F4){ref-type="fig"}** and data not shown). The development of natural regulatory T cells in the periphery appeared to be unaltered (**[Fig. 4b](#F4){ref-type="fig"}**). T cell proliferation in response to TCR--CD28 or PMA--ionomycin stimulation was also comparable in wild-type or *Mir210*^--/--^ T cells (**[Fig. 4c](#F4){ref-type="fig"}**). Therefore, miR-210 is not required for T cell development, homeostasis and proliferation.

*Hif1a* is a miR-210 target gene {#S7}
--------------------------------

To explore the role of miR-210 in T cell differentiation, we used an *in silico* analysis to identify potential target genes of miR-210. We identified miR-210 potential target genes in mouse T cells by performing the following two-step selection process. First, we used four algorithms, Target scan, PicTar, miRDB and miRanda^[@R34]-[@R37]^, to predict miR-210 target genes. All targets predicted by miRanda were scored for an empirical probability of target inhibition using mirSVR scores^[@R38]^and a stringent mirSVR score cutoff of -1.1. We combined this list with previously reported miR-210 targets, resulting in 69 potential miR-210 target genes (**[Supplementary Fig. 4b and Supplementary Table 1](#SD7){ref-type="supplementary-material"}**). Next, we selected for T cell-expressed target genes according to the Immgen data-base ([www.immgen.org](http://www.immgen.org)), resulting in 21 genes (**[Supplementary Fig. 4b and Supplementary Table 1](#SD7){ref-type="supplementary-material"}**). We compared their expression by RT-PCR in wild-type or *Mir210*^--/--^ CD4^+^ T cells, which were activated for 4 d. Assuming that miR-210--deficiency resulted in a higher expression of direct miR-210 targets, we identified five candidate genes that exhibited more than two-fold increased expression in *Mir210*^--/--^ CD4^+^ T cells (**[Fig. 5a](#F5){ref-type="fig"} and [Supplementary Fig. 4b](#SD7){ref-type="supplementary-material"}**). Two of these genes, *Iscu* and *Ndufa4*, were previously reported as miR-210 targets^[@R31],\ [@R39],\ [@R40]^. Surprisingly, *Hif1a*, was the highest upregulated (\>4 fold) miR-210 target gene (**[Fig. 5a](#F5){ref-type="fig"}**). To validate this observation, we compared HIF-1α protein in resting and TCR-stimulated wild-type or *Mir210*^--/--^ CD4^+^ T cells under normoxic or hypoxic conditions. Under hypoxia, we detected a marked and sustained increase in HIF-1α protein abundance in activated *Mir210*^--/--^ T cells (**[Fig. 5b](#F5){ref-type="fig"}**). Moreover, a moderate increase in HIF-1α protein was even detected in *Mir210*^--/--^ T cells activated for 3 or 4 d in normoxia (**[Fig. 5b](#F5){ref-type="fig"}**). These results support the notion that *Hif1a* is a miR-210 target gene, and that miR-210 adds an additional layer of regulation by curbing HIF-1α activity under hypoxia. The different kinetics of HIF-1α protein accumulation and degradation in stimulated wild-type CD4^+^ T cells under normoxia or hypoxia (**[Fig. 3b, 3c](#F3){ref-type="fig"}**), likely accounts for the fact that wild-type cells activated for 2 d under hypoxia had slightly lower HIF-1α protein abundance than cells activated under normoxia (**[Fig. 5b](#F5){ref-type="fig"}**). We determined whether ectopic expression of miR-210 decreased *Hif1a* transcript abundance. We reconstituted miR-210 expression in TCR-CD28--activated *Mir210*^--/--^ CD4^+^ T cells by transduction with bicistronic retroviruses expressing GFP and wild-type pri-miR-210 or GFP and a pri-miR-210 variant whose seed region was replaced by a scrambled control sequence (**[Fig. 5c](#F5){ref-type="fig"}**). We sorted GFP^+^ CD4^+^ T cells and found that *Hif1a* expression was markedly decreased by wild-type but not mutant miR-210 (**[Fig. 5d](#F5){ref-type="fig"}**).

*Hif1a* contains a non-canonical miR-210 targeting site in its 3′ UTR, containing one G:U wobble at position 7 of the 6-mer seed region. Recent HITS-CLIP studies revealed that a sizeable fraction of miRNA binding sites do not obey the seed pairing rule suggesting that non-canonical sites are widespread^[@R41],\ [@R42]^. One of these studies also provides a T cell-specific genome-wide argonaute (AGO) binding data set (CLIP Base), which enables analysis of target interactions with all miRNAs expressed in activated T cells^[@R42]^. CLIP Base shows a large peak of AGO binding to the *Hif1a* 3′ UTR at around 150 bp from the beginning of the 3′ UTR where the predicted miR-210 target site is located (**[Supplementary Fig. 5a](#SD7){ref-type="supplementary-material"}**). This potential miR-210 target site is highly conserved among multiple species, stressing its evolutionary importance (**[Supplementary Fig. 5b](#SD7){ref-type="supplementary-material"}**). To determine whether miR-210 binds this site directly, we cloned the full-length *Hif1a* 3′ UTR (\>1800 nucleotides) into a luciferase reporter construct, and cotransfected this reporter with miR-210 mimics into *Mir210*^--/--^ CD4^+^ T cells. A control luciferase reporter with a tandem stretch of four perfect miR-210 binding sites (miR-210 sensor) exhibited markedly reduced luciferase activity of the miR-210 sensor, indicating the miR-210 mimics do function *in vivo*. Interestingly, miR-210 expression also suppressed by about 30% the cotransfected *Hif1a* 3′ UTR reporter that contains only a single copy of the putative miR-210 binding (**[Fig. 5e](#F5){ref-type="fig"}**). Importantly, this suppression of *Hif1a* 3′ UTR by miR-210 was abolished by mutation of the miR-210 binding site. Thus, *Hif1a* is a *bona fide* target gene of miR-210.

miR-210 regulates T~H~17 polarization under reoxygenation {#S8}
---------------------------------------------------------

Since HIF-1 promotes T~H~17 differentiation^[@R15],\ [@R16]^, we investigated the potential role of miR-210 in T~H~17 cell differentiation *in vitro*. We compared the efficiency of wild-type or *Mir210*^--/--^ naive T cells to differentiate into T~H~17 cells in normoxia or an oxygen-limited environment. Under hypoxic conditions (1% O~2~), the expansion of activated T cells was severely impaired (**[Supplementary Fig. 5c](#SD7){ref-type="supplementary-material"}**). Therefore, reoxygenation conditions have been used to study T~H~17 cell differentiation^[@R43]^. Reoxygenation has been used to reflect the changes of O~2~ concentration experienced by migrating T cells *in vivo* and involves the differentiation of T~H~17 cells by a priming step under a low O~2~ concentration (5% O~2~) followed by transfer to normoxic conditions^[@R43]^ (**[Supplementary Fig. 6a](#SD7){ref-type="supplementary-material"}**). T~H~17 differentiation was promoted under reoxygenation versus normoxia under suboptimal (0.2 ng/ml IL-6), intermediate (2.0 ng/ml IL-6) or maximal (20.0 ng/ml IL-6) T~H~17 skewing conditions (**[Fig. 6a](#F6){ref-type="fig"}**). We used suboptimal IL-6 concentration (0.2 ng/ml) in subsequent analyses, since it showed the largest net increase in T~H~17 differentiation. Monitoring HIF-1α protein in T~H~17 cells polarized under normoxia or reoxygenation, we detected more HIF-1α protein in cells that were activated for 1 d under reoxygenation conditions, and a moderate increase in HIF-1α protein in cells polarized for 1, 2 or 3 d in normoxia (**[Fig. 6b](#F6){ref-type="fig"}**), suggesting a critical role for HIF-1α in T~H~17 differentiation in normoxia and reoxygenation conditions^[@R15],\ [@R16],\ [@R43]^. Consequently, CD4^+^ T cells polarized under reoxygenation conditions exhibited a more rapid and increased expression of miR-210 (**[Fig. 6c](#F6){ref-type="fig"}**), which was associated with a rapid decrease in HIF-1α protein between d 1 and d 2 (**[Fig. 6b, 6c](#F6){ref-type="fig"}**). Similar results were observed in activated T cells in nonpolarizing conditions (**[Supplementary Figure 6b,c](#SD7){ref-type="supplementary-material"}**). Notably, the increase of T~H~17 differentiation under reoxygenation, compared to normoxia, was reduced by about 50% in *Hif1a*^f/+^ CD4-Cre and was abolished in *Hif1a*^f/f^ CD4-Cre T cells, indicating that HIF-1α protein is limiting for the differentiation of T~H~17 cells under reoxygenation conditions (**[Fig. 6d](#F6){ref-type="fig"}**).

Whereas deficiency in miR-210 had subtle effects on T~H~17 differentiation under normoxic conditions, *Mir210* deletion markedly increased the proportion of T~H~17 cells under reoxygenation, especially if low or intermediate IL-6 concentrations were used (**[Fig. 7a,b](#F7){ref-type="fig"}**). By comparing wild-type or *Mir210*^--/--^ CD4^+^ T cells which were T~H~17 polarized under reoxygenation conditions, we observed that *Hif1a* transcript and HIF-1α protein amounts were increased in *Mir210*^--/--^ cells (**[Fig. 7c,d](#F7){ref-type="fig"}**). The increased HIF-1α protein was associated with marked up-regulation of genes encoding key regulators of the glycolytic pathway (**[Fig. 7e](#F7){ref-type="fig"}**), promoting T~H~17 differentiation^[@R16]^. This correlated well with increased expression of T~H~17 signature genes, including *Il17a*, *Il17f*, *Rorc* and *Il23r* (**[Fig. 7f](#F7){ref-type="fig"}**). Intriguingly, the observed increase in lineage differentiation under reoxygenation conditions, and the further polarization by deletion of *Mir210* exclusively applied for the T~H~17 subset (**[Supplementary Fig. 6d,e](#SD7){ref-type="supplementary-material"}**). Next, we investigated intracellular Foxp3 abundance in T~H~17-polarized wild-type or *Mir210*^--/--^ CD4^+^ T cells, skewed under suboptimal (0.2 ng/ml IL-6) T~H~17 conditions in normoxia or reoxygenation conditions. Normoxia-cultured cells exhibited a high proportion of Foxp3^+^ cells, irrespective whether they were miR-210--sufficient or --deficient (**[Supplementary Fig. 6f](#SD7){ref-type="supplementary-material"}**), consistent with reduced T~H~17 differentiation under those conditions (**[Fig. 6a](#F6){ref-type="fig"}**). In contrast, wild-type CD4^+^ T cells, skewed under reoxygenation conditions exhibited a decreased proportion of Foxp3^+^ cells (**[Supplementary Figure 6f](#SD7){ref-type="supplementary-material"}**), correlating well with increased T~H~17 differentiation potential (**[Fig. 6a](#F6){ref-type="fig"}**) and higher HIF-1α protein amounts (**[Fig. 6b](#F6){ref-type="fig"}**). *Mir210* deletion, which resulted in further increase of HIF-1α protein expression under reoxygenation (**[Fig. 7d](#F7){ref-type="fig"}**), caused a further drop of Foxp3^+^ cells (**[Supplementary Fig. 6f](#SD7){ref-type="supplementary-material"}**).

To substantiate the model that miR-210 attenuates T~H~17 differentiation by targeting *Hif1a*, we generated *Mir210*^--/--^*Hif1a*^f/+^mice, and compared the T~H~17 polarization potential of their naive T cells in normoxia or under reoxygenation to naive T cells of wild-type or *Mir210*^--/--^ mice (**[Fig. 7a](#F7){ref-type="fig"}**). Corroborating our previous results, the enhanced T~H~17 cell differentiation under reoxygenation caused by miR-210--deficiency was considerably suppressed in *Mir210*^--/--^*Hif1a*^f/+^ T cells, indicating that miR-210 regulates T~H~17 polarization mainly by targeting *Hif1a*.

miR-210 controls IBD severity {#S9}
-----------------------------

The gut is a hypoxic environment^[@R5]^ and contains a high proportion of IL-17A-producing cells^[@R15]^. To test whether miR-210 influences the differentiation of T~H~17 cells during an inflammatory bowel disease (IBD) model of colitis, we transferred naive, T~reg~-depleted (CD45.2^+^) T cells from wild-type or *Mir210*^--/--^ mice into CD45.1^+^*Rag2*^−/−^ mice. Five weeks after T cell transfer, wild-type T cells from the lamina propria contained a marked increase in miR-210 abundance compared to naive T cells (**[Fig. 8a](#F8){ref-type="fig"}**). Consistent with the reoxygenation *in vitro* model, miR-210--deficiency *in vivo* resulted in a markedly increased transcript and protein expression of HIF-1α in *Mir210*^--/--^ intestinal T cells (**[Fig. 8a,b](#F8){ref-type="fig"}**). In contrast, splenic T cells isolated from the same animals did not upregulate HIF-1α protein (**[Fig. 8b](#F8){ref-type="fig"}**). Both groups, the CD45.2^+^ wild-type T cell-transferred control and the CD45.2^+^*Mir210*^--/--^ T cell-transferred group, started to lose body weight about 3-4 weeks after T cell transfer. However, mice reconstituted with *Mir210*^--/--^ T cells exhibited substantially more weight loss, associated with increased mucosal leukocyte infiltration (**[Fig. 8c,d](#F8){ref-type="fig"}**). Moreover, the *Mir210*^--/--^ T cell-transferred group had higher weight/length ratios of the colon, which correlated with worse histopathological scores (**[Fig. 8e](#F8){ref-type="fig"}**), evidence of more severe disease in the absence of miR-210. We measured the percentages of IL-17A-producing cells among CD4^+^ T cells, isolated from the lamina propria of the sick animals and observed a marked increase in the proportion of IL-17A^+^ T cells in *Mir210*^--/--^ T cell-transferred mice, indicating that miR-210 controls T~H~17 differentiation *in vivo* (**[Fig. 8f](#F8){ref-type="fig"}**). Furthermore, the proportion of IL-17A^+^ interferon-γ (IFN-γ^+^) double-positive cells and IFN-γ^+^ single-positive cells were increased, indicating that miR-210--deficiency may also facilitate the conversion of T~H~1-like cells from T~H~17 cells (**[Fig. 8f](#F8){ref-type="fig"}**). Collectively, these results support an important role for miR-210 in controlling T~H~17 T cell differentiation and the development of immunopathology *in vivo*.

Discussion {#S10}
==========

In two independent global microRNA expression profiling studies in lymphocytes, miR-210 was shown to be induced in effector T cells^[@R25],\ [@R26]^. Our studies support and extend these findings by suggesting miR-210 plays a particularly important role in regulating the T~H~17 T cell lineage. We found that TCR stimulation led to a robust induction of *Mir210* in T cells under normoxic conditions. Moreover, hypoxia-challenged and antigen-stimulated T cells exhibited a more rapid and increased induction of *Mir210*, suggesting that multiple signals are required for optimal *Mir210* induction. Signals provided by antigen and costimulatory stimulation synergize with signals provided by the hypoxic environment. Immune cells encounter rapid changes in oxygen tension as they develop and migrate into different compartments of the body^[@R44]^. Therefore, a hypoxia-mediated signal to properly induce *Mir210* is an intriguing and additional layer of regulation for microRNAs critical in the immune system. *Mir210* is only fully induced when T cells are activated at inflammatory sites or in cancerous tissues, both of which are considered hypoxic^[@R45]^. What might be a possible biological function of this HIF-1α-induced microRNA under hypoxic conditions? miR-210 is not only upregulated by HIF-1α, but also negatively regulates *Hif1a* transcript and HIF-1α protein abundance in peripheral T cells, providing the first example of desensitizing HIF-1 activity by a microRNA in lymphocytes under hypoxic conditions.

In contrast to normoxia, hypoxic conditions inhibit HIF-1α degradation and lead to its stabilization^[@R8],\ [@R9]^. However, the mechanism by which HIF-1α activity is turned off to prevent its excessive activation in hypoxia was obscure. Two principal mechanisms have been proposed. First, although the hydroxylation activity of PHD is limited in hypoxia, the HIF-1α-driven increased expression of PHD2 and PHD3 under hypoxic conditions may compensate for the loss of their activities and consequently represents a negative-feedback loop targeting HIF-1α expression at the protein level^[@R46]-[@R48]^. Second, hypoxia-induced miR-155 directly targets *Hif1a* in intestinal epithelial cells, desensitizing HIF-1 activity at the transcript level^[@R10]^. However, we found that miR-155 is not a hypoxia-regulated microRNA in human or mouse T cells and suggest that the "hypoxamiR" miR-210 acts to specifically negatively regulate HIF-1α activity in T cells at later stages of activation.

Priming of naive T cells under O~2~-limiting (5%) conditions, significantly increases HIF-1α protein and thereby accelerates T~H~17 differentiation^[@R43]^. T cell-specific deletion of VHL, results in more HIF-1α and further increases T~H~17 differentiation under reoxygenation conditions^[@R43]^. We showed that HIF-1α-induced *Mir210* is highly expressed in T~H~17 cells and that miR-210 directly suppresses *Hif1a* transcript abundance. Therefore, miR-210 appears to play a role in feedback inhibition to curb HIF-1 activity in T cells under hypoxia and consequently restraining T~H~17 cell differentiation and associated immunopathology. This is consistent with less *Hif1a* in response to ectopic expression of miR-210 and a marked upregulation of *Hif1a* mRNA and protein in activated, *Mir210*^--/--^ T cells. This effect was most evident under reoxygenation conditions *in vitro* and in hypoxic environments *in vivo* suggesting that miR-210 plays its most important tuning role in low-oxygen conditions.

Consistent with many miRNA knockouts exhibiting phenotypes only under stress conditions^[@R49]^, *Mir210*^--/--^ T cells revealed enhanced T~H~17 polarization under reoxygenation, but not normoxia. Low oxygen tension increases the described HIF-1α--miR-210 regulatory feedback loop in two ways. Firstly, hypoxia synergizes with TCR-CD28 stimulation to prompt more rapid and robust induction of *Mir210*, which secondly leads to a more profound negative regulation of *Hif1a* mRNA, resulting in curbed HIF-1α activity in hypoxia. Therefore, miR-210 is a crucial regulator of HIF-1 activity and T~H~17 differentiation in low-oxygen conditions, which is further corroborated by our IBD studies.

HIF-1α has been suggested to be a potential therapeutic target for the treatment of a variety of T~H~17 cell-mediated autoimmune diseases^[@R15]^. Our *in vitro* and *in vivo* studies demonstrate that miR-210 is a potent regulator of *Hif1a* mRNA and protein in T cells under hypoxic conditions. Therefore, targeting *Hif1a* by administrating miR-210 mimics *in vivo* might be an effective therapeutic strategy for T~H~17-dependent autoimmune diseases.

Online Methods {#S11}
==============

Reagents {#S12}
--------

Rabbit polyclonal antibody against HIF-1α and mouse monoclonal antibody against GAPDH (Abcam, clone 6C5) were purchased from Cayman Chemical and Abcam, respectively. Anti--IL-4 (clone 11B11), anti--IFN-γ (clone XMG1.2), anti-CD3ε (clone 2C11) and anti-CD28 (clone 37.51) were purchased from UCSF Cell Culture Facility. CP550 690 was a gift from J.J. O\'Shea (NIH). GDC-0941 and MLN0128 were gifts from K. Shokat (UCSF). LY294002 and Rapamycin were purchased from Millipore. PMA and ionomycin were purchased from Sigma-Aldrich.

Mice {#S13}
----

The *Mir210* conditional knockout mice have been generated as described previously^[@R33]^. Briefly, *Mir210*^f/f^ mice were generated by crossing miR-210 (lacZ-*neo*^r^-flox) mice^[@R33]^ with the actin-Flp deleter mouse strain (Jax) to delete the lacZ--neomycin-resistance cassette, followed by backcrossing to the C57BL/6 (Jax) background for more than 9 generations. The C57BL/6 (Jax), *Cd28*^−/−^ (Jax), BoyJ (Taconic), CD45.1^+^CD45.2^--^*Rag2*^−/−^ (Taconic), CD4*-*Cre (Taconic), OTII (Taconic) and P14 TCR transgenic (Jax) mouse strains were purchased from the indicated vendors. *Il2*^--/--^ D011.10 mice and *Hif1a*^f/f^ mice have been described previously^[@R50],\ [@R51]^. All mice were housed and bred in specific-pathogen-free conditions in the Animal Barrier Facility at the University of California, San Francisco. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco.

RNA Analysis {#S14}
------------

For microRNA assays, total RNA was extracted with a mirVana miRNA Isolation Kit (Applied Biosystems) and then reverse transcribed with TaqMan Reverse Transcription reagents (Applied Biosystems). TaqMan miRNA assays were performed in an ABI Quantstudio machine (Applied Biosystems). miRNA assay results were normalized to the abundance of snoRNA202. The expression of each miRNA is presented as the fold change relative to its expression in wild-type naive T cells. For RT-PCR of non-miRNA genes, cDNA was synthesized with Superscript III/II reverse transcription (Invitrogen). The information of all primers is listed in **[Supplementary Table 2](#SD7){ref-type="supplementary-material"}**.

OVA Immunization and LCMV Infection {#S15}
-----------------------------------

For the activation of CD4^+^ T cells, splenic and lymph node-derived naive T cells (CD4^+^CD62L^hi^CD44^lo^CD25^--^) were sorted by flow cytometry from OT-II TCR-transgenic mice. After CFSE labeling, the sorted cells were transferred into congenic recipient mice. 24 h later, the recipients were immunized s.c. with the OVA323-339 peptide (100 μg/mouse Genscript) in the presence of Complete Freund\'s Adjuvant (CFA; DIFCO). Mice were sacrificed 7 d after immunization, and activated CD4^+^CFSE^lo^ T cells were isolated from the draining LN, followed by RNA isolation for miRNA expression analysis. For the *in vivo* activation of CD8^+^ T cells, P14 transgenic T cells were transferred into congenic recipient mice. The recipients were infected by lymphocytic choriomeningitis virus (LCMV). Naive (d 0), effector (d 8 post infection) and memory (d 202 post infection) LCMV-specific CD8^+^ T cells were sorted by flow cytometry, followed by RNA isolation for miRNA expression analysis.

*In vitro* T Cell Activation and Polarization Assays {#S16}
----------------------------------------------------

Sorted naive T cells (CD4^+^CD62L^hi^CD44^lo^CD25^--^) were used for *in vitro* culture in RPMI medium (plus β-mercaptoethanol) supplemented with 10% (vol/vol) FBS, 100 μM HEPES pH 7.5 and antibiotics. T cells were activated with plate-bound 2 μg/ml anti-CD3 (clone 2C11; UCSF Cell Culture Facility) and 2 μg/ml anti-CD28 (clone 37.51 UCSF Cell Culture Facility) for 4 d under conditions with various oxygen concentrations. For T~H~17 conditions, 10 μg/ml anti--IL-4, 10 μg/ml anti--IFN-γ, 2 ng/ml TGF-β, and 20, 2 or 0.2 ng/ml IL-6 were added to the cultures, and cells were stimulated for 3 d--5 d. Cells were then harvested and stimulated for a period of 5 h with PMA (50 ng/ml) and ionomycin (1 nM) in the presence of GolgiStop (BD-Biosciences), and the differentiated cells were analyzed by flow cytometry for cytokine production by intracellular staining using a LSRFortessa (BD-Biosciences). For the reoxygenation assay, T cells were firstly primed under a low O~2~ concentration (5% O~2~) for 36 h, and then the cells were transferred into a normoxic incubator for the rest of the culture.

Primary T cell Transfection, Luciferase Reporter Assays and Retroviral Transduction {#S17}
-----------------------------------------------------------------------------------

The lucifierase reporter assays and T cell transfection of miRNA mimics have been described previously^[@R52]^. Briefly, the full-length 3′ UTR of *Hif1a* was cloned into the pMIR-REPORT™ luciferase reporter construct (Invitrogen). Isolated naive CD4^+^ T cells were stimulated with anti-CD3 and anti-CD28 for 4 d. The activated T cells were cotransfected with reporter constructs and miRNA mimics (Dharmacon) by the Neon electroporation transfection system (Invitrogen) with an optimized version of the manufactures' recommended protocol. Luciferase activity was measured 24 h after transfection with the pMIR-REPORT™ miRNA Expression Reporter Vector System (Invitrogen) and a Mithras LB 940 (Berthold Technologies) platereader. Retroviral transduction was performed as described previously^[@R53]^.

Adoptive Transfer and Chronic Colitis model {#S18}
-------------------------------------------

The inflammatory bowel disease model has been described previously^[@R54]^. Briefly, 1 × 10^6^ flow-sorted naive T cells (CD4^+^CD25^--^CD44^--^CD62L^+^) were adoptively transferred i.p. into 8--12 week-old CD45.1^+^CD45.2^--^*Rag2*^−/−^ recipient mice (no specific randomization protocol was used). The body weight of each mouse was monitored after adoptive transfer. After mice were sacrificed, the colonic specimens taken from proximal and middle colons were subjected to histopathological assessment. Tissue samples were fixed in 10% neutral buffered formalin (pH7.0). Paraffin-embedded sections were stained with hematoxylin and eosin. These sections were analyzed and the severity of the inflammation was scored in a blinded manner. The degree of inflammation in the colon was graded according to a modification of the previously described scoring system^[@R54]^. Briefly, for mucosal damage, 0 points were assigned to normal appearance, 1 point to discrete lymphoepithelial lesions, 2 points to diffuse crypt elongation or goblet depletion, or 3 points to extensive crypt elongation, mucosal erosion/ulceration. For cell infiltration, 0 points were assigned for normal or for the presence of occasional leukocytes, 1 point for widely scattered leukocytes or focal aggregates of leukocytes, 2 points for the confluence of leukocytes extending into the submucosa with focal effacement of the muscularis, or 3 points for transmural extension of leukocyte infiltration. For crypt abscess, the assigned points were: 0 for no crypt abscess; 1 point for the presence of rare crypt abscess; or, 2 points for multiple crypt abscesses.

Statistical Analysis {#S19}
--------------------

Prism software was used for statistical analysis. Differences between groups were compared by unpaired two-tailed *t*-test. A *P* value of less than 0.05 was considered statistically significant.
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![*Mir210* is induced after T cell activation and regulated during T cell differentiation. (**a**) The expression of miR-210 or *Il2* in activated T cells was assessed by RT-PCR. The data were normalized by miR-210 expression in naive T cells (n=3 independent biological replicates per data point). (**b**) Homeostatically expanded CD4^+^ T cells were sorted from various tissues 3 weeks after adoptive transfer. The expression of miR-210 and miR-155 were assessed by RT-PCR. (**c**) miR-210 and miR-155 expression within *in vivo* activated OTII CD4^+^ T cells were determined by RT-PCR. (**d**) After 4 d polarizing naive CD4^+^ T cells towards the T~H~1, T~H~2, T~H~17 or iTreg lineage, cells with selective expression of IFN-γ, IL-4, IL-17A or Foxp3 were assessed by flow cytometry with the percentages of gated cells depicted (top). The time dependency of miR-210 expression in polarized T cells was measured by RT-PCR (bottom). Relative expression is normalized to sno202. Data are from one experiment representative of two (**b**,**c**) or three (**d**) independent experiments (mean and s.d. in **a**--**d**).](nihms-566200-f0001){#F1}

![CD28-costimulation controls *Mir210* expression via the PI(3)K-mTOR pathway. (**a**) Naive CD4^+^ T cells were activated by anti-CD3 in the presence or absence of anti-CD28 for 4 d and miR-210 expression was analyzed by RT-PCR. (**b**) RT-PCR analysis of miR-182 and miR-210 expression in activated T cells from wild-type or *Il2*^−/−^ DO11.10 *Rag2*^−/−^ mice. (**c**) CD4^+^ naive T cells were stimulated in the presence of the kinase inhibitors CP550 690 (100 nM), GDC-0941 (1 μM), LY294002 (5 μM), Rapamycin (20 nM) or MLN0128 (200 nM). miR-210 expression was measured by RTPCR. Relative expression is normalized to sno202 (n=3 independent biological replicates per data point). Data are from one experiment representative of three (**a**) independent experiments (mean and s.d. in **a**--**c**, \* *P*\<0.05, unpaired *t*-test in **b**, abbreviations: Rest, resting; Act, activated; UT, untreated).](nihms-566200-f0002){#F2}

![HIF-1α is required for *Mir210* induction\
(**a**) Quantitative RT-PCR analysis of miR-210 abundance in unstimulated or anti-CD3-- anti-CD28 stimulated CD4^+^ T cells. Cells were induced for a period of 4 d under normoxic (21% O~2~) or hypoxic (1% O~2~) conditions and RNA was harvested at the indicated time points. Relative miR-210 expression is normalized to its expression in naive T cells. (**b**) Immunoblot analysis with a HIF-1α-specific or GAPDH-specific antibody in total protein lysates of unstimulated or anti-CD3--anti-CD28 stimulated CD4^+^ T cells. Cells were induced for a period of 4 d under normoxic (21% O~2~) or hypoxic (1% O~2~) conditions and protein was harvested at the indicated time points. (**c**) Densitometric analysis of HIF-1α protein levels shown in (**b**) in comparison to miR-210 expression levels presented in (**a**). (**d**) Quantitative RT-PCR analysis of *Hif1a,* miR-210, and miR-182 transcripts in resting or stimulated wild-type (*Hif1a*^+/+^CD4-cre) or HIF-1α--deficient (*Hif1a*^f/f^CD4-cre) CD4^+^ T cells. Relative expression is normalized to β*2* (*Hif1a*) or sno202 (miR-210 and miR-182) and n=3 independent biological replicates per data point. Data are from one experiment representative of three (**a**--**c**) independent experiments. (mean and s.d. in a,c,d; abbreviations: Rest, resting; Act, activated; ND not detectable).](nihms-566200-f0003){#F3}

![miR-210--deficiency has no apparent effect on T cell development and proliferation\
(**a**) Flow cytometry analysis of thymocytes (top panels) or gated double negative thymocytes (bottom panels) from 7 weeks old wild-type or *Mir210*^--/--^ mice, stained with anti-CD4 and anti-CD8 or anti-CD44 and anti-CD25. Numbers adjacent to (or in) outlined areas indicate percent cells in each throughout. (**b**) The surface expression of CD4, CD8 (top), CD44, CD62L (middle) or CD25 and the intracellular expression of Foxp3 (bottom) in splenocytes derived from 7 weeks old wild-type or *Mir210*^--/--^ mice were assessed by flow cytometry. (**c**) T cell proliferation was analyzed in triplicate samples by ^3^H-thymidine uptake 72 h after stimulation with either anti-CD3 or PMA plus ionomycin (mean and s.d.). Data are representative of three (**a**--**c**) independent experiments.](nihms-566200-f0004){#F4}

![miR-210 directly targets *Hif1a*\
(**a**) RT-PCR analysis of the expression of predicted miR-210 target and control gene transcripts in anti-CD3--anti-CD28--stimulated wild-type or *Mir210*^--/--^ CD4^+^ T cells. The genes with more than 2-fold upregulation were highlighted. (**b**) Naive CD4^+^ T cells from wild-type (WT) or *Mir210*^--/--^ (KO) mice were activated by anti-CD3--anti-CD28 under normoxic (21% O~2~) or hypoxic (1% O~2~) conditions for 4 d and HIF-1α as well as GAPDH protein abundance was detected by immunoblot analysis. (**c**) Sequence alignment between miR-210 and the 3′ UTR of *Hif1a*. The mutated sequences in seed regions of miR-210 and *Hif1a* are highlighted in bold figures. (**d**) *Mir210*^--/--^ CD4^+^ T cells were anti-CD3 plus anti-CD28 stimulated for 36 h, transduced with bicistronic retroviruses expressing GFP (Vector), GFP and wild-type pri-miR-210 (miR-210 WT) or GFP and mutated pri-miR-210 (miR-210 mutant) followed by RT-PCR analysis for *Hif1a* and miR-210 expression in GFP^+^, CD4^+^ T cells at 84 h. (**e**) *Mir210*^--/--^ CD4^+^ T cells were cotransfected with luciferase reporters and miR-210 or control miRNA mimics. Luciferase activity was measured 24 h after transfection and was normalized to control transfected cells. (\* *P\<*0.05, n=4 independent biological replicates per data point *t*-test). Data are from one experiment representative of two (**a**,**b**) or three (**d**) independent experiments. (mean and s.d. in **a**,**d**,**e**).](nihms-566200-f0005){#F5}

![Priming of naive T cells under reoxygenation increases miR-210 abundance\
(**a**) Naive CD4^+^ T cells were polarized towards T~H~17 cells with titrated doses of IL-6 under normoxic or reoxygenation conditions (**[Supplementary Fig. 6a](#SD7){ref-type="supplementary-material"}**), followed by intracellular staining of IL-17A and IFN-γ. (**b--c**) Immunoblot analysis of HIF-1α and GAPDH and RT-PCR analysis of miR-210 in T~H~17 cells polarized under normoxic or reoxygenation conditions (0.2 ng/ml of IL-6). Relative miR-210 abundance was normalized to its expression in naive T cells. (**d**) Naive CD4^+^ T cells from *Hif1a*^+/+^CD4-Cre, *Hif1a*^f/+^CD4-Cre or *Hif1a*^f/f^CD4-Cre mice were differentiated under T~H~17 skewing conditions with 0.2 ng/ml of IL-6 under normoxic or reoxygenation conditions, followed by intracellular staining of IL-17A and IFN-γ. Data are representative of two (**b**,**c**,**d**) or three (**a**) independent experiments. (mean and s.d. in **c**).](nihms-566200-f0006){#F6}

![miR-210**--**deficiency along with reoxygenation conditions markedly increases T~H~17 differentiation\
(**a**) Naive CD4^+^ T cells from wild-type (*Mir210*^+/+^CD4-Cre), *Mir210*^--/--^ (*Mir210*^f/f^CD4-Cre) or *Hif1a*^f/+^*Mir210*^f/f^CD4-Cre mice were differentiated under T~H~17 skewing conditions (0.2 ng/ml of IL-6), followed by intracellular staining of IL-17A and IFN-γ. (**b**) Naive CD4^+^ T cells from wild-type (*Mir210*^+/+^CD4-Cre) or *Mir210*^--/--^ (*Mir210*^f/f^CD4-Cre) mice were differentiated under T~H~17 skewing conditions with varying doses of IL-6 under normoxic or reoxygenetion conditions, followed by intracellular staining of IL-17A and IFN-γ. (**c--d**) Wild-type or *Mir210*^--/--^ T cells were T~H~17 differentiated under reoxygenetion conditions as described in (**a)** for 3 d. Transcripts of miR-210 and *Hif1a* were detected by RT-PCR analysis; HIF-1α and GAPDH protein levels were detected by immunoblot analysis. (**e--f**) Quantitative RT-PCR analysis of HIF-1α target genes of the glycolytic pathway *(Eno1, Glut1, Ldha, Pkm, Slc16a3 and Tpi)* and T~H~17 signature genes (*Il17a*, *Il17f*, *Rorc* and *Il23r)* in wild-type or *Mir210*^--/--^ CD4^+^ T~H~17 cells that were differentiated under reoxygenetion conditions. Relative expression is normalized to sno202 (miR-210) or β*-2m* (the rest of genes). Data are from one experiment representative of two (**a** right, **d**,**e**), three (**c**,**f**) or four (**a** left and middle, **b**) independent experiments. (mean and s.d. in **b**,**c**,**e**,**f**).](nihms-566200-f0007){#F7}

![miR-210 in T cells ameliorates IBD disease in a CD4^+^ T cell transfer model of colitis\
(**a**) Wild-type (*Mir210*^+/+^CD4-Cre) or *Mir210*^--/--^ (*Mir210*^f/f^CD4-Cre) naive T cells were transferred into *Rag2*^−/−^ recipient mice. Five weeks later, the colons from recipient mice were excised and lamina propria CD4^+^ T cells were isolated from the colon. Naive CD4^+^ T cells were included as a control. miR-210 abundance and *Hif1a* transcripts were analyzed by RT-PCR analysis. (**b**) HIF-1α as well as GAPDH protein abundance in CD4^+^ T cells isolated from spleen or lamina propria of *Rag2*^−/−^ recipient mice described in (**a**) was detected by immunoblot analysis. (**c**) Change in body weight of *Rag2*^−/−^ recipient mice given wild-type or *Mir210*^--/--^ naive T cells (n=9 per group). (**d**) Histopathology of distal colon at 5.5 weeks after transfer. Original magnification, X100. (**e**) Ratio of colon weight vs colon length (n=8--9 per group) and histopathological score (n=6--8 per group) of each group are shown. (**f**) Expression of IL-17A and IFN-γ in CD4^+^ T cells isolated from lamina propria (n=3--4 mice per group). \* *P\<*0.05, \*\* *P\<*0.001, unpaired *t*-test. Data are from one experiment representative of two (**a**--**f**) independent experiments.](nihms-566200-f0008){#F8}
